The goal of this interventional study is to compare the efficacy of Atropine 0.05% to
Atropine 0.5% treatment against progression of axial length in European children with
progressive myopia, and to evaluate the safety, adherence, and reasons for nonresponse.
Subjects will use Atropine eye drops for a period of 3 years, followed by a 2 year
observational period.
Phase:
Phase 3
Details
Lead Sponsor:
Erasmus Medical Center
Collaborator:
ZonMw: The Netherlands Organisation for Health Research and Development